Alto Neuroscience Inc. announced a repricing of certain stock options for its employees and consultants, effective July 3, 2025. The repricing applies to options granted under the company's 2019 and 2024 Equity Incentive Plans, specifically targeting options with exercise prices over $2.35 per share. This move affects options held by key executives, including CEO Dr. Amit Etkin, CFO Nicholas Smith, and COO Michael Hanley. The repricing initiative impacts a total of 4,225,763 shares, with the aim to adjust the exercise prices of options that are currently "underwater," meaning their exercise prices exceed the current market value of the company's stock. The new terms require participants to remain with the company through a specified Retention Period to exercise the options at the reduced price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.